Leveraging its extended blood circulation and precise tumor targeting via PEGylated shell and GE11-modified HA backbone, nanoCRISPR activates its self-cascade mechanism upon encountering the MMP2 enzyme-rich tumor microenvironment. This evidence concerns the gene MMP2 and neoplasm.